<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673929</url>
  </required_header>
  <id_info>
    <org_study_id>CCR5156</org_study_id>
    <nct_id>NCT04673929</nct_id>
  </id_info>
  <brief_title>Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract</brief_title>
  <acronym>RECUT</acronym>
  <official_title>Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      transoral Robotic surgery for rECurrent tumours of the Upper aerodigestive Tract&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Head and neck cancer (HNC) is the 6th most common type of cancer in the world and is&#xD;
      increasing in incidence. Squamous cell carcinomas (SCC) account for the majority of these&#xD;
      HNCs. An increasing number of these SCCs are being found to be associated with the Human&#xD;
      Papilloma Virus (HPV) which has also been shown to be associated with a more favourable&#xD;
      outcome. These HPV related cancers tend to affect younger patients with fewer comorbidities.&#xD;
      As such, we are finding a larger cohort of patients are surviving for longer after treatment&#xD;
      for their primary cancers.&#xD;
&#xD;
      HNC patients are over 11 times more likely to experience a second head and neck primary&#xD;
      cancer than the general population over 20 years of follow up (SIR 11.2, 95% CI [10.6-11.8]).&#xD;
      In addition to second primaries, patients may suffer from residual disease after treatment&#xD;
      for their initial primary, identified within a 12 month period, or recurrent disease, cancer&#xD;
      at the same site identified within 5 years. Treatment for all of these cancers, which we will&#xD;
      broadly term 'recurrent' cancers for the purposes of this study, can be complex. Commonly,&#xD;
      radiotherapy will have formed part of the treatment regime at either the primary site or to&#xD;
      the neck for these patients. Radiotherapy causes fibrosis in the irradiated tissues, reducing&#xD;
      tissue pliability, contributing to trismus and reducing healing potential at the effected&#xD;
      sites. This can pose significant challenges to any further surgical intervention, which may&#xD;
      form the mainstay of any subsequent management if re-irradiation is not an option or not&#xD;
      indicated. Surgery must then look to be as minimally invasive as possible in order to&#xD;
      maximise functional outcomes and reduce disruption of affected tissues.&#xD;
&#xD;
      Options for surgery have traditionally involved transmandibular and transcervical routes.&#xD;
      More recently transoral routes have been adopted as endoscopic instruments become more widely&#xD;
      available and adopted. Transoral Robotic Surgery (TORS) is the latest development in the&#xD;
      field which confers some significant advantages to the surgeon and to the patient. For the&#xD;
      surgeon, the endoscopic view is binocular, giving a close objective lens and excellent depth&#xD;
      perception. Further, the instruments have wrists which sit within the body cavity, allowing&#xD;
      manipulation of the tissues beyond the direct line of sight through the oral stoma. For the&#xD;
      patient, there is less disrupted tissue if access incisions are avoided, reducing the volume&#xD;
      of tissue that would be susceptible to scarring which can affect swallowing function or lead&#xD;
      to fistula formation.&#xD;
&#xD;
      However, there are little data to show oncological and functional outcomes are acceptable&#xD;
      following TORS surgery for recurrent cancers. This is in part as it is a relatively new&#xD;
      technology and in part because whilst increasingly common, the absolute number of surgeries&#xD;
      performed remains relatively low at individual centres. Published outcomes have shown 2 year&#xD;
      disease-free survival rates around 75%. The RECUT study aims to use a collaborative&#xD;
      methodology to document the outcomes from TORS for recurrent HNC being performed at a number&#xD;
      of high volume centres across the globe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival at 2 years</measure>
    <time_frame>24 months</time_frame>
    <description>Disease-free survival at 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 2 years</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival at 2 years</measure>
    <time_frame>24 months</time_frame>
    <description>Disease-specific survival at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of gastrostomy use at 1 year</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of gastrostomy use at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of tracheostomy use at 1 year</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of tracheostomy use at 1 year</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Recurrent Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>patients with HNC recurrence treated with TORS</arm_group_label>
    <description>Report of disease-free survival at 2 years for patients with HNC recurrence treated with TORS</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals aged over 18 with previous HNC treated with radiotherapy and undergoing TORS as&#xD;
        part of their management for recurrent disease. Surgery performed on or before July 31st&#xD;
        2018.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged over 18&#xD;
&#xD;
          -  Previous HNC treated with radiotherapy&#xD;
&#xD;
          -  Undergoing TORS as part of their management for recurrent disease&#xD;
&#xD;
          -  Surgery performed on or before July 31st 2018.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  TORS used in a diagnostic setting only&#xD;
&#xD;
          -  Nasopharyngeal and thyroid cancers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Head and Neck Unit, Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hardman</last_name>
      <phone>442073528171</phone>
      <email>johncharles.hardman@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Marta Vergnano</last_name>
      <email>marta.vergnano@rmh.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Gandolfi</last_name>
      <phone>02086613903</phone>
      <email>ann.gandolfi@rmh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </reference>
  <reference>
    <citation>Shield KD, Ferlay J, Jemal A, Sankaranarayanan R, Chaturvedi AK, Bray F, Soerjomataram I. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin. 2017 Jan;67(1):51-64. doi: 10.3322/caac.21384. Epub 2016 Oct 19.</citation>
    <PMID>28076666</PMID>
  </reference>
  <reference>
    <citation>INTEGRATE (The National ENT Trainee Research Network). British Association of Head and Neck Oncologists Surveillance audit 2018. Unpublished</citation>
  </reference>
  <reference>
    <citation>Chuang SC, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Kliewer EV, Hemminki K, Weiderpass E, Pukkala E, Tracey E, Friis S, Pompe-Kirn V, Brewster DH, Martos C, Chia KS, Boffetta P, Brennan P, Hashibe M. Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. Int J Cancer. 2008 Nov 15;123(10):2390-6. doi: 10.1002/ijc.23798.</citation>
    <PMID>18729183</PMID>
  </reference>
  <reference>
    <citation>Gross ND, Hanna EY. The Role of Surgery in the Management of Recurrent Oropharyngeal Cancer. Recent Results Cancer Res. 2017;206:197-205. Review.</citation>
    <PMID>27699540</PMID>
  </reference>
  <reference>
    <citation>Paleri V, Fox H, Coward S, Ragbir M, McQueen A, Ahmed O, Meikle D, Saleh D, O'Hara J, Robinson M. Transoral robotic surgery for residual and recurrent oropharyngeal cancers: Exploratory study of surgical innovation using the IDEAL framework for early-phase surgical studies. Head Neck. 2018 Mar;40(3):512-525. doi: 10.1002/hed.25032. Epub 2017 Dec 15.</citation>
    <PMID>29244229</PMID>
  </reference>
  <reference>
    <citation>Hamilton D, Paleri V. Role of transoral robotic surgery in current head &amp; neck practice. Surgeon. 2017 Jun;15(3):147-154. doi: 10.1016/j.surge.2016.09.004. Epub 2016 Oct 11. Review.</citation>
    <PMID>27742406</PMID>
  </reference>
  <reference>
    <citation>Weinstein GS, O'Malley BW Jr, Cohen MA, Quon H. Transoral robotic surgery for advanced oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2010 Nov;136(11):1079-85. doi: 10.1001/archoto.2010.191.</citation>
    <PMID>21079160</PMID>
  </reference>
  <reference>
    <citation>White H, Ford S, Bush B, Holsinger FC, Moore E, Ghanem T, Carroll W, Rosenthal E, Sweeny L, Magnuson JS. Salvage surgery for recurrent cancers of the oropharynx: comparing TORS with standard open surgical approaches. JAMA Otolaryngol Head Neck Surg. 2013 Aug 1;139(8):773-8. doi: 10.1001/jamaoto.2013.3866. Erratum in: JAMA Otolaryngol Head Neck Surg.n 2013 Dec;139(12):1290. Sweeny, Larissa [added].</citation>
    <PMID>23949352</PMID>
  </reference>
  <reference>
    <citation>Dabas S, Dewan A, Ranjan R, Dewan AK, Shukla H, Sinha R. Salvage Transoral Robotic Surgery for Recurrent or Residual Head and Neck Squamous Cell Carcinoma: A Single Institution Experience. Asian Pac J Cancer Prev. 2015;16(17):7627-32.</citation>
    <PMID>26625773</PMID>
  </reference>
  <reference>
    <citation>Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000 Apr;110(4):593-602.</citation>
    <PMID>10764003</PMID>
  </reference>
  <reference>
    <citation>Paleri V, Wight RG. Applicability of the adult comorbidity evaluation - 27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study. J Laryngol Otol. 2002 Mar;116(3):200-5.</citation>
    <PMID>11893262</PMID>
  </reference>
  <reference>
    <citation>Microsoft. Excel for Mac [Internet]. Redmond, Washington, USA: Microsoft Corporation; 2018. Available from: https://products.office.com/</citation>
  </reference>
  <reference>
    <citation>R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2013. Available from: http://www.R-project.org/</citation>
  </reference>
  <reference>
    <citation>RStudio Team. RStudio: Integrated Development Environment for R [Internet]. Boston, MA: RStudio, Inc.; 2015. Available from: http://www.rstudio.com/</citation>
  </reference>
  <reference>
    <citation>ICMJE | Recommendations | Defining the Role of Authors and Contributors [Internet]. [cited 2019 Jan 23];Available from: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent head and neck cancer</keyword>
  <keyword>transoral robotic surgery</keyword>
  <keyword>TORS</keyword>
  <keyword>HNC recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT04673929/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

